PT88013A - Processo para a preparacao de isomeros opticos de derivados imidazolicos e de composicoes farmaceuticas que os contem - Google Patents

Processo para a preparacao de isomeros opticos de derivados imidazolicos e de composicoes farmaceuticas que os contem

Info

Publication number
PT88013A
PT88013A PT198888013A PT8801388A PT88013A PT 88013 A PT88013 A PT 88013A PT 198888013 A PT198888013 A PT 198888013A PT 8801388 A PT8801388 A PT 8801388A PT 88013 A PT88013 A PT 88013A
Authority
PT
Portugal
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
optical isomers
imidazolic
Prior art date
Application number
PT198888013A
Other languages
English (en)
Other versions
PT88013B (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT88013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PT88013A publication Critical patent/PT88013A/pt
Publication of PT88013B publication Critical patent/PT88013B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT88013A 1987-07-16 1988-07-15 Processo para a preparacao de isomeros opticos de derivados imidazolicos e de composicoes farmaceuticas que os contem PT88013B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative

Publications (2)

Publication Number Publication Date
PT88013A true PT88013A (pt) 1989-06-30
PT88013B PT88013B (pt) 1995-03-01

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88013A PT88013B (pt) 1987-07-16 1988-07-15 Processo para a preparacao de isomeros opticos de derivados imidazolicos e de composicoes farmaceuticas que os contem

Country Status (29)

Country Link
US (1) US4910214A (pt)
EP (1) EP0300652B1 (pt)
JP (1) JPH0625138B2 (pt)
KR (1) KR940007311B1 (pt)
CN (1) CN1022323C (pt)
AT (1) ATE71941T1 (pt)
AU (1) AU600839B2 (pt)
BG (1) BG60473B2 (pt)
CA (1) CA1337659C (pt)
CY (2) CY1787A (pt)
DD (1) DD281807A5 (pt)
DE (2) DE3867945D1 (pt)
DK (1) DK165788C (pt)
ES (1) ES2038757T3 (pt)
FI (1) FI95375C (pt)
GB (1) GB2206880B (pt)
GR (1) GR3003878T3 (pt)
HK (1) HK56094A (pt)
HU (1) HU198693B (pt)
IE (1) IE60456B1 (pt)
IL (1) IL87076A0 (pt)
LU (1) LU91010I2 (pt)
NL (1) NL300117I2 (pt)
NO (2) NO170579C (pt)
NZ (1) NZ225362A (pt)
PT (1) PT88013B (pt)
SU (1) SU1648248A3 (pt)
UA (1) UA5560A1 (pt)
ZA (1) ZA885134B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (pt) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
JP4741131B2 (ja) 1999-10-29 2011-08-03 オリオン コーポレーション 低血圧およびショックの治療または予防
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
RU2435569C2 (ru) 2006-03-16 2011-12-10 Трис Фарма, Инк. Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
EP2370136A4 (en) * 2008-12-01 2015-12-30 Map Pharmaceuticals Inc INHALATIVE RELEASE PROCEDURES AND DEVICES
WO2010074753A1 (en) * 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
PE20120713A1 (es) * 2009-05-15 2012-07-08 Recro Pharma Inc Composiciones sublinguales de dexmedetomidina y metodos para su uso
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
SG10201604653TA (en) 2011-12-11 2016-07-28 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
ES2717469T3 (es) 2012-08-15 2019-06-21 Tris Pharma Inc Comprimido masticable de metilfenidato de liberación prolongada
PL2906213T3 (pl) 2012-10-15 2018-04-30 Orion Corporation Weterynaryjny sposób łagodzenia awersji wobec hałasu
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
CN105175339B (zh) * 2015-10-09 2018-01-16 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Also Published As

Publication number Publication date
HU198693B (en) 1989-11-28
FI882819A0 (fi) 1988-06-14
CA1337659C (en) 1995-11-28
SU1648248A3 (ru) 1991-05-07
NO170579B (no) 1992-07-27
HK56094A (en) 1994-06-03
DK386288A (da) 1989-01-17
DK386288D0 (da) 1988-07-11
HUT48218A (en) 1989-05-29
GR3003878T3 (pt) 1993-03-16
AU600839B2 (en) 1990-08-23
DK165788B (da) 1993-01-18
IE882174L (en) 1989-01-16
PT88013B (pt) 1995-03-01
CN1030576A (zh) 1989-01-25
EP0300652A1 (en) 1989-01-25
KR940007311B1 (ko) 1994-08-12
BG60473B2 (bg) 1995-04-28
ES2038757T3 (es) 1993-08-01
JPH0625138B2 (ja) 1994-04-06
EP0300652B1 (en) 1992-01-22
CN1022323C (zh) 1993-10-06
US4910214A (en) 1990-03-20
IE60456B1 (en) 1994-07-13
IL87076A0 (en) 1988-12-30
ATE71941T1 (de) 1992-02-15
GB2206880A (en) 1989-01-18
NO883155D0 (no) 1988-07-15
NO883155L (no) 1989-01-17
FI882819A (fi) 1989-01-17
JPS6434968A (en) 1989-02-06
DD281807A5 (de) 1990-08-22
CY2004006I2 (el) 2009-11-04
NL300117I1 (nl) 2003-05-01
NL300117I2 (nl) 2003-10-01
CY2004006I1 (el) 2009-11-04
DE3867945D1 (de) 1992-03-05
AU1894188A (en) 1989-01-19
FI95375B (fi) 1995-10-13
ZA885134B (en) 1989-04-26
NO170579C (no) 1992-11-04
DK165788C (da) 1993-06-14
NZ225362A (en) 1990-07-26
NO2003004I2 (no) 2005-03-21
LU91010I2 (fr) 2003-06-19
GB8716803D0 (en) 1987-08-19
GB2206880B (en) 1991-04-24
DE10399005I2 (de) 2012-06-06
DE10399005I1 (de) 2003-06-05
UA5560A1 (uk) 1994-12-28
FI95375C (fi) 1996-01-25
CY1787A (en) 1995-10-20
KR890002030A (ko) 1989-04-07

Similar Documents

Publication Publication Date Title
PT88013A (pt) Processo para a preparacao de isomeros opticos de derivados imidazolicos e de composicoes farmaceuticas que os contem
PT96394A (pt) Processo para a preparacao de novos derivados do acido a-nor-esteroide-3-carboxilico e de composicoes farmaceuticas que os contem
PT87201A (pt) Processo para a preparacao de novos derivados de cefalosporina 3,7-substituida e de composicoes farmaceuticas que os contem
PT89009A (pt) Processo para a preparacao de novos derivados de fluorocitidina e composicoes farmaceuticas que os contem
PT89793A (pt) Processo de preparacao de derivados de quinolina substituidos e de composicoes farmaceuticas que os contem
PT87913A (pt) Processo para a preparacao de derivados de benzopirano e de composicoes farmaceuticas que os contem
PT82097B (pt) Processo para a preparacao de derivados de labdano e de composicoes farmaceuticas que os contem
PT83355B (pt) Processo para a preparacao de derivados de benzimidazole e de composicoes farmaceuticas que os contem
PT83559B (pt) Processo para a preparacao de novos derivados de indol e indazol-ceto-sulfona e de composicoes farmaceuticas que os contem
PT89311A (pt) Processo para a preparacao de novos aminoalcoxi-p-benzonitrilos substituidos utilizaveis como agentes antiarritmicos e de composicoes farmaceuticas que os contem
PT81843B (pt) Processo para a preparacao de derivados de imida ciclicos de 2-(4-butilpiperazinil-1)-piridinas com actividade antipsicotica e de composicoes farmaceuticas que os contem
PT88351A (pt) Processo para a preparacao de derivados de isoxazol-beta-carbolina e de composicoes farmaceuticas que os contem
PT87090A (pt) Processo para a preparacao de derivados de imidazopiridinas e de composicoes farmaceuticas que os contem
PT84794B (pt) Processo de preparacao de derivados de benzimidazois substituido e de composicoes farmaceuticas que os contem
PT84428B (pt) Processo para a preparacao de derivados de acidos 1-metil-1h-imidazol-5- -carboxilicos e de composicoes herbicidas que os contem
PT88917A (pt) Processo para a preparacao de derivados de piridoxal-hidrazona e de composicoes farmaceuticas que os contem
PT91051A (pt) Processo para a preparacao de novos derivados de glicerina e de composicoes farmaceuticas que os contem
PT93064A (pt) Processo para a preparacao de derivados de fenil-sulfona e de composicoes farmaceuticas que os contem
PT87304A (pt) Processo para a preparacao de derivados de benzenosulfonamida e de composicoes farmaceuticas que os contem
PT88054A (pt) Processo para a preparacao de derivados de benzotiazinona e de composicoes farmaceuticas que os contem
PT83491B (pt) Processo para a preparacao de um novo derivado do tiocromano
PT88762A (pt) Processo para a preparacao de peroxidos biciclicos e de composicoes farmaceuticas que os contem
PT88923A (pt) Processo para a preparacao de derivados de acillabdano e de composicoes farmaceuticas que os contem
PT87883A (pt) Processo para a preparacao de derivados de cefem e de composicoes farmaceuticas que os contem
PT89106A (pt) Processo para a preparacao de novos derivados de labdano e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19940819

PD3A Change of proprietorship

Free format text: ORION CORPORATION FI

Effective date: 20030224

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20090819